Amber Littlefield
Psychiatric/Mental Health · Broussard, LANPI 1538440094
Payments from drug & device makers
Across 1,120 payments — averaging $200.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$134K
- AbbVie$82K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Sunovion Pharmaceuticals Inc.$972
- plus $5K from 25 others
What the payments were for
- Consulting fees$57,36426%
- Speaking & faculty fees$138,59262%
- Travel & lodging$11,6325%
- Food & beverage$16,9368%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 249 | $133,638 |
| AbbVie | 327 | $81,734 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 69 | $1,097 |
| Otsuka America Pharmaceutical, Inc. | 66 | $1,081 |
| Alkermes, Inc. | 56 | $1,035 |
| Sunovion Pharmaceuticals Inc. | 99 | $972 |
| Corium, LLC | 39 | $599 |
| Lundbeck LLC | 24 | $505 |
| Neurocrine Biosciences, Inc. | 23 | $501 |
| Johnson & Johnson | 25 | $491 |
| Tris Pharma Inc | 24 | $462 |
| Noven Therapeutics, LLC | 19 | $354 |
| Braeburn Inc. | 15 | $323 |
| Vanda Pharmaceuticals Inc. | 11 | $244 |
| Bausch Health US, LLC | 12 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $230 |
| Indivior Inc. | 10 | $222 |
| Supernus Pharmaceuticals, Inc. | 9 | $161 |
| Eisai Inc. | 7 | $123 |
| E.r. Squibb & Sons, L.L.C. | 2 | $122 |
| Ironshore Pharmaceuticals Inc. | 4 | $80 |
| Teva Pharmaceuticals USA, Inc. | 3 | $65 |
| Merck | 4 | $61 |
| Neos Therapeutics, LP | 3 | $54 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Sage Therapeutics, LLC | 1 | $35 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Noven Pharmaceuticals, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$224,535 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 69 | $97,528 |
| RexultiBrexpiprazole | 15 | $20,749 |
| TrintellixVortioxetine Hydrobromide | 17 | $8,097 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $2,918 |
| Lurasidone Hcl | 26 | $2,044 |
| Duloxetine Hcl | 123 | $1,081 |
| Oxcarbazepine | 13 | $996 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $642 |
| Trazodone Hcl | 124 | $530 |
| Bupropion XlBupropion Hcl | 33 | $494 |
| Atomoxetine Hcl | 12 | $437 |
| Escitalopram Oxalate | 62 | $362 |
| Fluoxetine Hcl | 46 | $355 |
| Buspirone Hcl | 65 | $336 |
| Quetiapine Fumarate | 40 | $305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $81,734 | $97,52869 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,081 | $20,74915 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $230 | $8,09717 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $19346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Broussard
- Aimee Chantelle BroussardBroussard$13K
- Natalie BlanchardBroussard$12K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.